Ikonisys FY25 net loss widens to EUR 4.2 million; net sales rise 37.3% to EUR 1.39 million

• Ikonisys posted FY 2025 net sales of €1.39 million, up 37.3%.
• Net loss widened to €4.2 million; operating loss widened to €3.9 million.
• EBITDA loss narrowed to €1.14 million from €1.7 million.
• Cash and cash equivalents rose to €1.03 million at year-end.
• Update: US patent for ACTA, Urine24 launched in Italy, exclusive Italian distribution deal signed with Menarini Diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikonisys SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260730279932) on July 30, 2026, and is solely responsible for the information contained therein.